News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,022 Results
Type
Article (44270)
Company Profile (467)
Press Release (704271)
Multimedia
Podcasts (145)
Webinars (23)
Section
Business (209552)
Career Advice (2049)
Deals (36232)
Drug Delivery (140)
Drug Development (84170)
Employer Resources (174)
FDA (16811)
Job Trends (15232)
News (354745)
Policy (33306)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2691)
Accelerated approval (54)
Adcomms (31)
Allergies (179)
Alliances (51126)
ALS (223)
Alzheimer's disease (1870)
Antibody-drug conjugate (ADC) (507)
Approvals (17191)
Artificial intelligence (716)
Autoimmune disease (324)
Automation (57)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (228)
Biotechnology (325)
Bladder cancer (204)
Brain cancer (77)
Breast cancer (791)
Cancer (6201)
Cardiovascular disease (507)
Career advice (1743)
Career pathing (45)
CAR-T (351)
CDC (59)
Celiac Disease (3)
Cell therapy (966)
Cervical cancer (49)
Clinical research (73010)
Collaboration (2212)
Company closure (5)
Compensation (1445)
Complete response letters (91)
COVID-19 (2813)
CRISPR (119)
C-suite (1205)
Cystic fibrosis (163)
Data (8341)
Decentralized trials (3)
Denatured (46)
Depression (176)
Dermatology (93)
Diabetes (610)
Diagnostics (7031)
Digital health (57)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (352)
Drug pricing (213)
Drug shortages (32)
Duchenne muscular dystrophy (309)
Earnings (93471)
Editorial (70)
Employer branding (21)
Employer resources (153)
Events (123849)
Executive appointments (1130)
FDA (20671)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1831)
Gene editing (258)
Generative AI (58)
Gene therapy (792)
GLP-1 (1113)
Government (4842)
Grass and pollen (6)
Guidances (413)
Healthcare (19432)
HIV (84)
Huntington's disease (59)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (107)
Immunology and inflammation (323)
Immuno-oncology (107)
Indications (199)
Infectious disease (3170)
Inflammatory bowel disease (229)
Inflation Reduction Act (17)
Influenza (140)
Intellectual property (303)
Interviews (319)
IPO (16960)
IRA (53)
Job creations (3719)
Job search strategy (1443)
JPM (67)
Kidney cancer (19)
Labor market (105)
Layoffs (602)
Leadership (42)
Legal (8032)
Liver cancer (104)
Longevity (34)
Lung cancer (829)
Lymphoma (448)
Machine learning (61)
Management (59)
Manufacturing (1098)
MASH (209)
Medical device (14103)
Medtech (14236)
Mergers & acquisitions (20533)
Metabolic disorders (1610)
mRNA (243)
Multiple sclerosis (198)
NASH (20)
Neurodegenerative disease (461)
Neuropsychiatric disorders (115)
Neuroscience (3495)
Neurotech (1)
NextGen: Class of 2026 (6775)
Non-profit (4606)
Now hiring (79)
Obesity (761)
Opinion (314)
Ovarian cancer (235)
Pain (266)
Pancreatic cancer (327)
Parkinson's disease (393)
Partnered (34)
Patents (613)
Patient recruitment (712)
Peanut (63)
People (61141)
Pharmaceutical (79)
Pharmacy benefit managers (34)
Phase 1 (22969)
Phase 2 (32216)
Phase 3 (23786)
Pipeline (9273)
Policy (338)
Postmarket research (2607)
Preclinical (9852)
Press Release (67)
Prostate cancer (330)
Psychedelics (64)
Radiopharmaceuticals (358)
Rare diseases (1170)
Real estate (6083)
Recruiting (71)
Regulatory (26075)
Reports (56)
Research institute (2517)
Resumes & cover letters (355)
Rett syndrome (39)
RNA editing (27)
RSV (88)
Schizophrenia (187)
Series A (309)
Series B (227)
Service/supplier (11)
Sickle cell disease (121)
Special edition (29)
Spinal muscular atrophy (171)
Sponsored (49)
Startups (3838)
State (2)
Stomach cancer (19)
Supply chain (132)
Tariffs (88)
The Weekly (96)
Vaccines (1150)
Venture capital (121)
Weight loss (494)
Women's health (132)
Worklife (21)
Date
Today (180)
Last 7 days (758)
Last 30 days (3329)
Last 365 days (31088)
2026 (14221)
2025 (31063)
2024 (36286)
2023 (41012)
2022 (52276)
2021 (56760)
2020 (54917)
2019 (47414)
2018 (35693)
2017 (33025)
2016 (32347)
2015 (38396)
2014 (32189)
2013 (27110)
2012 (29222)
2011 (29866)
2010 (27996)
Location
Africa (759)
Alabama (99)
Alaska (7)
Arizona (362)
Arkansas (16)
Asia (41286)
Australia (6874)
California (13813)
Canada (3870)
China (1460)
Colorado (590)
Connecticut (612)
Delaware (419)
Europe (90842)
Florida (2040)
Georgia (440)
Hawaii (3)
Idaho (63)
Illinois (1117)
India (93)
Indiana (619)
Iowa (25)
Japan (563)
Kansas (135)
Kentucky (52)
Louisiana (45)
Maine (76)
Maryland (1648)
Massachusetts (9982)
Michigan (374)
Minnesota (745)
Mississippi (6)
Missouri (147)
Montana (35)
Nebraska (29)
Nevada (145)
New Hampshire (89)
New Jersey (3630)
New Mexico (32)
New York (3591)
North Carolina (1805)
North Dakota (10)
Northern California (6943)
Ohio (409)
Oklahoma (23)
Oregon (44)
Pennsylvania (2750)
Puerto Rico (29)
Rhode Island (51)
South America (1126)
South Carolina (86)
South Dakota (2)
Southern California (5421)
Tennessee (216)
Texas (2189)
United States (48815)
Utah (408)
Vermont (1)
Virginia (332)
Washington D.C. (82)
Washington State (1128)
West Virginia (4)
Wisconsin (135)
Wyoming (2)
749,022 Results for "sirna therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.
May 7, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting
May 27, 2026
·
3 min read
Press Releases
The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy
• Vial’s INHBE siRNA is a first‑in‑class, liver‑targeted (GalNAc‑conjugated) siRNA therapy that silences INHBE and its gene product, Activin E • Leading key opinion leaders (KOLs) Drs. Jason Fung, Scott Kahan, Lawrence Cheskin, and Lee Kaplan from leading institutions such as Johns Hopkins, GMU, and Dartmouth University respectively shared their insights on challenges with current GLP-1 treatments as well as the potential benefits of INHBE siRNA therapies like Vial’s • INHBE siRNAs are designed to deliver fat-selective weight loss while preserving lean muscle mass • Vial’s INHBE siRNA will be investigated for its potential as both a mono-therapy and in combination with GLP-1s to offer patients flexibility on their weight loss journey
December 16, 2025
·
1 min read
Press Releases
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
May 5, 2026
·
11 min read
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
MASH
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead
Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.
May 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
December 16, 2025
·
1 min read
Press Releases
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
January 8, 2026
·
6 min read
Press Releases
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 25, 2026
·
1 min read
Press Releases
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
March 25, 2026
·
9 min read
1 of 74,903
Next